Idexx Laboratories

IDXX

Market cap $44.8B

IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Fecal Dx™ antigen testing with taeniid tapeworm detection for broader intestinal parasite screening in wellness and sick-pet care.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX integrates SDMA into most common Catalyst chemistry profiles, enabling earlier detection of kidney disease through routine in‑clinic testing.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 27, 2026 from 10:55 am – 11:25 am (ET). A live audio webcast of the presentation will be available through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will b.

IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript

IDXX rides strong on Q1 beats with rising margins; lifts 2026 outlook as diagnostics growth and innovation momentum fuel performance.

The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Idexx Laboratories Inc (NASDAQ:IDXX) shares are up on Tuesday as the company recently announced strong first-quarter results, showcasing a 14% revenue growth.

Idexx stock jumped early Tuesday on better-than-expected first-quarter sales and earnings. The firm raised its 2026 guidance.

Idexx Laboratories (IDXX) came out with quarterly earnings of $3.47 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.96 per share a year ago.